Our response to COVID-19
At the beginning of the pandemic, we streamlined the COVID-19 research set-up process in the UK by establishing a single, collective UK system-wide approach involving NIHR, Public Health England, UK Research & Innovation (UKRI), the Health Research Authority (HRA), Medicines and Healthcare products Regulatory Agency (MHRA) and others.
Due to the drop in COVID-19 case numbers and significant progress with the vaccine roll-out, we are no longer accepting applications for studies to be designated as Urgent Public Health (UPH). However existing UPH studies will continue to be prioritised over the coming weeks, and new COVID-19 portfolio studies will be supported in line with local priorities and capacity. Find out more about NIHR support for COVID-19 research.
You can read examples of how our support has helped, such as:
You may also find the following resources useful:
Managing research recovery
With the pressures of the pandemic beginning to ease and COVID-19 caseloads falling, work is underway to support the recovery of research into other conditions, and to increase the strength of the UK’s research base and life sciences sector. This supports the vision set out by the Department of Health and Social Care in the document Saving and Improving Lives: the future of UK clinical research delivery.
Find out how we are managing recovery and work to support non-COVID 19 studies to improve research recovery, resilience and growth.
- if you have questions about the pausing or restart of a clinical study: email@example.com
- if you are from a company wanting to be connected to the NIHR's expert researchers: firstname.lastname@example.org